Global PD-1 and PDL-1 Inhibitors Market Growth 2025-2031
The report requires updating with new data and is sent in 48 hours after order is placed.
The global PD-1 and PDL-1 Inhibitors market size is predicted to grow from US$ 47240 million in 2025 to US$ 71940 million in 2031; it is expected to grow at a CAGR of 7.3% from 2025 to 2031.
PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.
North America is the largest consumption place, with a consumption market share nearly 60.40% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 20.66%.Market competition is intense. Merck, Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical etc. are the leaders of the industry.
LP Information, Inc. (LPI) ' newest research report, the “PD-1 and PDL-1 Inhibitors Industry Forecast” looks at past sales and reviews total world PD-1 and PDL-1 Inhibitors sales in 2024, providing a comprehensive analysis by region and market sector of projected PD-1 and PDL-1 Inhibitors sales for 2025 through 2031. With PD-1 and PDL-1 Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PD-1 and PDL-1 Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global PD-1 and PDL-1 Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PD-1 and PDL-1 Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global PD-1 and PDL-1 Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PD-1 and PDL-1 Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PD-1 and PDL-1 Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of PD-1 and PDL-1 Inhibitors market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global PD-1 and PDL-1 Inhibitors market?
What factors are driving PD-1 and PDL-1 Inhibitors market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do PD-1 and PDL-1 Inhibitors market opportunities vary by end market size?
How does PD-1 and PDL-1 Inhibitors break out by Type, by Application?
The global PD-1 and PDL-1 Inhibitors market size is predicted to grow from US$ 47240 million in 2025 to US$ 71940 million in 2031; it is expected to grow at a CAGR of 7.3% from 2025 to 2031.
PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.
North America is the largest consumption place, with a consumption market share nearly 60.40% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 20.66%.Market competition is intense. Merck, Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical etc. are the leaders of the industry.
LP Information, Inc. (LPI) ' newest research report, the “PD-1 and PDL-1 Inhibitors Industry Forecast” looks at past sales and reviews total world PD-1 and PDL-1 Inhibitors sales in 2024, providing a comprehensive analysis by region and market sector of projected PD-1 and PDL-1 Inhibitors sales for 2025 through 2031. With PD-1 and PDL-1 Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PD-1 and PDL-1 Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global PD-1 and PDL-1 Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PD-1 and PDL-1 Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global PD-1 and PDL-1 Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PD-1 and PDL-1 Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PD-1 and PDL-1 Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of PD-1 and PDL-1 Inhibitors market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Pembrolizumab
- Nivolumab
- Atezolizumab
- Durvalumab
- Avelumab
- Stomach Cancer
- Liver Cancer
- Kidney Ccancer
- Bladder Cancer
- Cervical Cancer
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- GlaxoSmithKline plc
- Bristol-Myers Squibb Company
- Arcus Biosciences, Inc.
- Agenus Inc
- F. Hoffmann-La Roche Ltd
- Astra Zeneca PLC
- Beigene Ltd
- Incyte Corporation
- Biocad
- CStone Pharmaceuticals
- Ono Pharmaceutical
- Merck
- Shanghai Junshi Bioscience Co. Ltd
- Shanghai Henlius Biotech, Inc.
- Jiangsu HengRui Medicine Co., Ltd.
What is the 10-year outlook for the global PD-1 and PDL-1 Inhibitors market?
What factors are driving PD-1 and PDL-1 Inhibitors market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do PD-1 and PDL-1 Inhibitors market opportunities vary by end market size?
How does PD-1 and PDL-1 Inhibitors break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global PD-1 and PDL-1 Inhibitors Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for PD-1 and PDL-1 Inhibitors by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for PD-1 and PDL-1 Inhibitors by Country/Region, 2020, 2024 & 2031
2.2 PD-1 and PDL-1 Inhibitors Segment by Type
2.2.1 Pembrolizumab
2.2.2 Nivolumab
2.2.3 Atezolizumab
2.2.4 Durvalumab
2.2.5 Avelumab
2.3 PD-1 and PDL-1 Inhibitors Sales by Type
2.3.1 Global PD-1 and PDL-1 Inhibitors Sales Market Share by Type (2020-2025)
2.3.2 Global PD-1 and PDL-1 Inhibitors Revenue and Market Share by Type (2020-2025)
2.3.3 Global PD-1 and PDL-1 Inhibitors Sale Price by Type (2020-2025)
2.4 PD-1 and PDL-1 Inhibitors Segment by Application
2.4.1 Stomach Cancer
2.4.2 Liver Cancer
2.4.3 Kidney Ccancer
2.4.4 Bladder Cancer
2.4.5 Cervical Cancer
2.4.6 Other
2.5 PD-1 and PDL-1 Inhibitors Sales by Application
2.5.1 Global PD-1 and PDL-1 Inhibitors Sale Market Share by Application (2020-2025)
2.5.2 Global PD-1 and PDL-1 Inhibitors Revenue and Market Share by Application (2020-2025)
2.5.3 Global PD-1 and PDL-1 Inhibitors Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global PD-1 and PDL-1 Inhibitors Breakdown Data by Company
3.1.1 Global PD-1 and PDL-1 Inhibitors Annual Sales by Company (2020-2025)
3.1.2 Global PD-1 and PDL-1 Inhibitors Sales Market Share by Company (2020-2025)
3.2 Global PD-1 and PDL-1 Inhibitors Annual Revenue by Company (2020-2025)
3.2.1 Global PD-1 and PDL-1 Inhibitors Revenue by Company (2020-2025)
3.2.2 Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Company (2020-2025)
3.3 Global PD-1 and PDL-1 Inhibitors Sale Price by Company
3.4 Key Manufacturers PD-1 and PDL-1 Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers PD-1 and PDL-1 Inhibitors Product Location Distribution
3.4.2 Players PD-1 and PDL-1 Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PD-1 AND PDL-1 INHIBITORS BY GEOGRAPHIC REGION
4.1 World Historic PD-1 and PDL-1 Inhibitors Market Size by Geographic Region (2020-2025)
4.1.1 Global PD-1 and PDL-1 Inhibitors Annual Sales by Geographic Region (2020-2025)
4.1.2 Global PD-1 and PDL-1 Inhibitors Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic PD-1 and PDL-1 Inhibitors Market Size by Country/Region (2020-2025)
4.2.1 Global PD-1 and PDL-1 Inhibitors Annual Sales by Country/Region (2020-2025)
4.2.2 Global PD-1 and PDL-1 Inhibitors Annual Revenue by Country/Region (2020-2025)
4.3 Americas PD-1 and PDL-1 Inhibitors Sales Growth
4.4 APAC PD-1 and PDL-1 Inhibitors Sales Growth
4.5 Europe PD-1 and PDL-1 Inhibitors Sales Growth
4.6 Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Growth
5 AMERICAS
5.1 Americas PD-1 and PDL-1 Inhibitors Sales by Country
5.1.1 Americas PD-1 and PDL-1 Inhibitors Sales by Country (2020-2025)
5.1.2 Americas PD-1 and PDL-1 Inhibitors Revenue by Country (2020-2025)
5.2 Americas PD-1 and PDL-1 Inhibitors Sales by Type (2020-2025)
5.3 Americas PD-1 and PDL-1 Inhibitors Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PD-1 and PDL-1 Inhibitors Sales by Region
6.1.1 APAC PD-1 and PDL-1 Inhibitors Sales by Region (2020-2025)
6.1.2 APAC PD-1 and PDL-1 Inhibitors Revenue by Region (2020-2025)
6.2 APAC PD-1 and PDL-1 Inhibitors Sales by Type (2020-2025)
6.3 APAC PD-1 and PDL-1 Inhibitors Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe PD-1 and PDL-1 Inhibitors by Country
7.1.1 Europe PD-1 and PDL-1 Inhibitors Sales by Country (2020-2025)
7.1.2 Europe PD-1 and PDL-1 Inhibitors Revenue by Country (2020-2025)
7.2 Europe PD-1 and PDL-1 Inhibitors Sales by Type (2020-2025)
7.3 Europe PD-1 and PDL-1 Inhibitors Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa PD-1 and PDL-1 Inhibitors by Country
8.1.1 Middle East & Africa PD-1 and PDL-1 Inhibitors Sales by Country (2020-2025)
8.1.2 Middle East & Africa PD-1 and PDL-1 Inhibitors Revenue by Country (2020-2025)
8.2 Middle East & Africa PD-1 and PDL-1 Inhibitors Sales by Type (2020-2025)
8.3 Middle East & Africa PD-1 and PDL-1 Inhibitors Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of PD-1 and PDL-1 Inhibitors
10.3 Manufacturing Process Analysis of PD-1 and PDL-1 Inhibitors
10.4 Industry Chain Structure of PD-1 and PDL-1 Inhibitors
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 PD-1 and PDL-1 Inhibitors Distributors
11.3 PD-1 and PDL-1 Inhibitors Customer
12 WORLD FORECAST REVIEW FOR PD-1 AND PDL-1 INHIBITORS BY GEOGRAPHIC REGION
12.1 Global PD-1 and PDL-1 Inhibitors Market Size Forecast by Region
12.1.1 Global PD-1 and PDL-1 Inhibitors Forecast by Region (2026-2031)
12.1.2 Global PD-1 and PDL-1 Inhibitors Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global PD-1 and PDL-1 Inhibitors Forecast by Type (2026-2031)
12.7 Global PD-1 and PDL-1 Inhibitors Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 GlaxoSmithKline plc
13.1.1 GlaxoSmithKline plc Company Information
13.1.2 GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.1.3 GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 GlaxoSmithKline plc Main Business Overview
13.1.5 GlaxoSmithKline plc Latest Developments
13.2 Bristol-Myers Squibb Company
13.2.1 Bristol-Myers Squibb Company Company Information
13.2.2 Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.2.3 Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Bristol-Myers Squibb Company Main Business Overview
13.2.5 Bristol-Myers Squibb Company Latest Developments
13.3 Arcus Biosciences, Inc.
13.3.1 Arcus Biosciences, Inc. Company Information
13.3.2 Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.3.3 Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Arcus Biosciences, Inc. Main Business Overview
13.3.5 Arcus Biosciences, Inc. Latest Developments
13.4 Agenus Inc
13.4.1 Agenus Inc Company Information
13.4.2 Agenus Inc PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.4.3 Agenus Inc PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Agenus Inc Main Business Overview
13.4.5 Agenus Inc Latest Developments
13.5 F. Hoffmann-La Roche Ltd
13.5.1 F. Hoffmann-La Roche Ltd Company Information
13.5.2 F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.5.3 F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 F. Hoffmann-La Roche Ltd Main Business Overview
13.5.5 F. Hoffmann-La Roche Ltd Latest Developments
13.6 Astra Zeneca PLC
13.6.1 Astra Zeneca PLC Company Information
13.6.2 Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.6.3 Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Astra Zeneca PLC Main Business Overview
13.6.5 Astra Zeneca PLC Latest Developments
13.7 Beigene Ltd
13.7.1 Beigene Ltd Company Information
13.7.2 Beigene Ltd PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.7.3 Beigene Ltd PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Beigene Ltd Main Business Overview
13.7.5 Beigene Ltd Latest Developments
13.8 Incyte Corporation
13.8.1 Incyte Corporation Company Information
13.8.2 Incyte Corporation PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.8.3 Incyte Corporation PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Incyte Corporation Main Business Overview
13.8.5 Incyte Corporation Latest Developments
13.9 Biocad
13.9.1 Biocad Company Information
13.9.2 Biocad PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.9.3 Biocad PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Biocad Main Business Overview
13.9.5 Biocad Latest Developments
13.10 CStone Pharmaceuticals
13.10.1 CStone Pharmaceuticals Company Information
13.10.2 CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.10.3 CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 CStone Pharmaceuticals Main Business Overview
13.10.5 CStone Pharmaceuticals Latest Developments
13.11 Ono Pharmaceutical
13.11.1 Ono Pharmaceutical Company Information
13.11.2 Ono Pharmaceutical PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.11.3 Ono Pharmaceutical PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Ono Pharmaceutical Main Business Overview
13.11.5 Ono Pharmaceutical Latest Developments
13.12 Merck
13.12.1 Merck Company Information
13.12.2 Merck PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.12.3 Merck PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Merck Main Business Overview
13.12.5 Merck Latest Developments
13.13 Shanghai Junshi Bioscience Co. Ltd
13.13.1 Shanghai Junshi Bioscience Co. Ltd Company Information
13.13.2 Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.13.3 Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Shanghai Junshi Bioscience Co. Ltd Main Business Overview
13.13.5 Shanghai Junshi Bioscience Co. Ltd Latest Developments
13.14 Shanghai Henlius Biotech, Inc.
13.14.1 Shanghai Henlius Biotech, Inc. Company Information
13.14.2 Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.14.3 Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Shanghai Henlius Biotech, Inc. Main Business Overview
13.14.5 Shanghai Henlius Biotech, Inc. Latest Developments
13.15 Jiangsu HengRui Medicine Co., Ltd.
13.15.1 Jiangsu HengRui Medicine Co., Ltd. Company Information
13.15.2 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.15.3 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Jiangsu HengRui Medicine Co., Ltd. Main Business Overview
13.15.5 Jiangsu HengRui Medicine Co., Ltd. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. PD-1 and PDL-1 Inhibitors Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. PD-1 and PDL-1 Inhibitors Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Pembrolizumab
Table 4. Major Players of Nivolumab
Table 5. Major Players of Atezolizumab
Table 6. Major Players of Durvalumab
Table 7. Major Players of Avelumab
Table 8. Global PD-1 and PDL-1 Inhibitors Sales byType (2020-2025) & (K Units)
Table 9. Global PD-1 and PDL-1 Inhibitors Sales Market Share byType (2020-2025)
Table 10. Global PD-1 and PDL-1 Inhibitors Revenue byType (2020-2025) & ($ million)
Table 11. Global PD-1 and PDL-1 Inhibitors Revenue Market Share byType (2020-2025)
Table 12. Global PD-1 and PDL-1 Inhibitors Sale Price byType (2020-2025) & (US$/Unit)
Table 13. Global PD-1 and PDL-1 Inhibitors Sale by Application (2020-2025) & (K Units)
Table 14. Global PD-1 and PDL-1 Inhibitors Sale Market Share by Application (2020-2025)
Table 15. Global PD-1 and PDL-1 Inhibitors Revenue by Application (2020-2025) & ($ million)
Table 16. Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Application (2020-2025)
Table 17. Global PD-1 and PDL-1 Inhibitors Sale Price by Application (2020-2025) & (US$/Unit)
Table 18. Global PD-1 and PDL-1 Inhibitors Sales by Company (2020-2025) & (K Units)
Table 19. Global PD-1 and PDL-1 Inhibitors Sales Market Share by Company (2020-2025)
Table 20. Global PD-1 and PDL-1 Inhibitors Revenue by Company (2020-2025) & ($ millions)
Table 21. Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Company (2020-2025)
Table 22. Global PD-1 and PDL-1 Inhibitors Sale Price by Company (2020-2025) & (US$/Unit)
Table 23. Key Manufacturers PD-1 and PDL-1 Inhibitors Producing Area Distribution and Sales Area
Table 24. Players PD-1 and PDL-1 Inhibitors Products Offered
Table 25. PD-1 and PDL-1 Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global PD-1 and PDL-1 Inhibitors Sales by Geographic Region (2020-2025) & (K Units)
Table 29. Global PD-1 and PDL-1 Inhibitors Sales Market Share Geographic Region (2020-2025)
Table 30. Global PD-1 and PDL-1 Inhibitors Revenue by Geographic Region (2020-2025) & ($ millions)
Table 31. Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Geographic Region (2020-2025)
Table 32. Global PD-1 and PDL-1 Inhibitors Sales by Country/Region (2020-2025) & (K Units)
Table 33. Global PD-1 and PDL-1 Inhibitors Sales Market Share by Country/Region (2020-2025)
Table 34. Global PD-1 and PDL-1 Inhibitors Revenue by Country/Region (2020-2025) & ($ millions)
Table 35. Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Country/Region (2020-2025)
Table 36. Americas PD-1 and PDL-1 Inhibitors Sales by Country (2020-2025) & (K Units)
Table 37. Americas PD-1 and PDL-1 Inhibitors Sales Market Share by Country (2020-2025)
Table 38. Americas PD-1 and PDL-1 Inhibitors Revenue by Country (2020-2025) & ($ millions)
Table 39. Americas PD-1 and PDL-1 Inhibitors Sales byType (2020-2025) & (K Units)
Table 40. Americas PD-1 and PDL-1 Inhibitors Sales by Application (2020-2025) & (K Units)
Table 41. APAC PD-1 and PDL-1 Inhibitors Sales by Region (2020-2025) & (K Units)
Table 42. APAC PD-1 and PDL-1 Inhibitors Sales Market Share by Region (2020-2025)
Table 43. APAC PD-1 and PDL-1 Inhibitors Revenue by Region (2020-2025) & ($ millions)
Table 44. APAC PD-1 and PDL-1 Inhibitors Sales byType (2020-2025) & (K Units)
Table 45. APAC PD-1 and PDL-1 Inhibitors Sales by Application (2020-2025) & (K Units)
Table 46. Europe PD-1 and PDL-1 Inhibitors Sales by Country (2020-2025) & (K Units)
Table 47. Europe PD-1 and PDL-1 Inhibitors Revenue by Country (2020-2025) & ($ millions)
Table 48. Europe PD-1 and PDL-1 Inhibitors Sales byType (2020-2025) & (K Units)
Table 49. Europe PD-1 and PDL-1 Inhibitors Sales by Application (2020-2025) & (K Units)
Table 50. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales by Country (2020-2025) & (K Units)
Table 51. Middle East & Africa PD-1 and PDL-1 Inhibitors Revenue Market Share by Country (2020-2025)
Table 52. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales byType (2020-2025) & (K Units)
Table 53. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales by Application (2020-2025) & (K Units)
Table 54. Key Market Drivers & Growth Opportunities of PD-1 and PDL-1 Inhibitors
Table 55. Key Market Challenges & Risks of PD-1 and PDL-1 Inhibitors
Table 56. Key IndustryTrends of PD-1 and PDL-1 Inhibitors
Table 57. PD-1 and PDL-1 Inhibitors Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. PD-1 and PDL-1 Inhibitors Distributors List
Table 60. PD-1 and PDL-1 Inhibitors Customer List
Table 61. Global PD-1 and PDL-1 Inhibitors SalesForecast by Region (2026-2031) & (K Units)
Table 62. Global PD-1 and PDL-1 Inhibitors RevenueForecast by Region (2026-2031) & ($ millions)
Table 63. Americas PD-1 and PDL-1 Inhibitors SalesForecast by Country (2026-2031) & (K Units)
Table 64. Americas PD-1 and PDL-1 Inhibitors Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 65. APAC PD-1 and PDL-1 Inhibitors SalesForecast by Region (2026-2031) & (K Units)
Table 66. APAC PD-1 and PDL-1 Inhibitors Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 67. Europe PD-1 and PDL-1 Inhibitors SalesForecast by Country (2026-2031) & (K Units)
Table 68. Europe PD-1 and PDL-1 Inhibitors RevenueForecast by Country (2026-2031) & ($ millions)
Table 69. Middle East & Africa PD-1 and PDL-1 Inhibitors SalesForecast by Country (2026-2031) & (K Units)
Table 70. Middle East & Africa PD-1 and PDL-1 Inhibitors RevenueForecast by Country (2026-2031) & ($ millions)
Table 71. Global PD-1 and PDL-1 Inhibitors SalesForecast byType (2026-2031) & (K Units)
Table 72. Global PD-1 and PDL-1 Inhibitors RevenueForecast byType (2026-2031) & ($ millions)
Table 73. Global PD-1 and PDL-1 Inhibitors SalesForecast by Application (2026-2031) & (K Units)
Table 74. Global PD-1 and PDL-1 Inhibitors RevenueForecast by Application (2026-2031) & ($ millions)
Table 75. GlaxoSmithKline plc Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 76. GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 77. GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. GlaxoSmithKline plc Main Business
Table 79. GlaxoSmithKline plc Latest Developments
Table 80. Bristol-Myers Squibb Company Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 81. Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 82. Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Bristol-Myers Squibb Company Main Business
Table 84. Bristol-Myers Squibb Company Latest Developments
Table 85. Arcus Biosciences, Inc. Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 86. Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 87. Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Arcus Biosciences, Inc. Main Business
Table 89. Arcus Biosciences, Inc. Latest Developments
Table 90. Agenus Inc Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 91. Agenus Inc PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 92. Agenus Inc PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Agenus Inc Main Business
Table 94. Agenus Inc Latest Developments
Table 95.F. Hoffmann-La Roche Ltd Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 96.F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 97.F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98.F. Hoffmann-La Roche Ltd Main Business
Table 99.F. Hoffmann-La Roche Ltd Latest Developments
Table 100. Astra Zeneca PLC Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 101. Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 102. Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Astra Zeneca PLC Main Business
Table 104. Astra Zeneca PLC Latest Developments
Table 105. Beigene Ltd Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 106. Beigene Ltd PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 107. Beigene Ltd PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Beigene Ltd Main Business
Table 109. Beigene Ltd Latest Developments
Table 110. Incyte Corporation Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 111. Incyte Corporation PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 112. Incyte Corporation PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Incyte Corporation Main Business
Table 114. Incyte Corporation Latest Developments
Table 115. Biocad Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 116. Biocad PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 117. Biocad PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Biocad Main Business
Table 119. Biocad Latest Developments
Table 120. CStone Pharmaceuticals Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 121. CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 122. CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. CStone Pharmaceuticals Main Business
Table 124. CStone Pharmaceuticals Latest Developments
Table 125. Ono Pharmaceutical Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 126. Ono Pharmaceutical PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 127. Ono Pharmaceutical PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Ono Pharmaceutical Main Business
Table 129. Ono Pharmaceutical Latest Developments
Table 130. Merck Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 131. Merck PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 132. Merck PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. Merck Main Business
Table 134. Merck Latest Developments
Table 135. Shanghai Junshi Bioscience Co. Ltd Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 136. Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 137. Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 138. Shanghai Junshi Bioscience Co. Ltd Main Business
Table 139. Shanghai Junshi Bioscience Co. Ltd Latest Developments
Table 140. Shanghai Henlius Biotech, Inc. Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 141. Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 142. Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 143. Shanghai Henlius Biotech, Inc. Main Business
Table 144. Shanghai Henlius Biotech, Inc. Latest Developments
Table 145. Jiangsu HengRui Medicine Co., Ltd. Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 146. Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 147. Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 148. Jiangsu HengRui Medicine Co., Ltd. Main Business
Table 149. Jiangsu HengRui Medicine Co., Ltd. Latest Developments
LIST OFFIGURES
Figure 1. Picture of PD-1 and PDL-1 Inhibitors
Figure 2. PD-1 and PDL-1 Inhibitors Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global PD-1 and PDL-1 Inhibitors Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global PD-1 and PDL-1 Inhibitors Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. PD-1 and PDL-1 Inhibitors Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. PD-1 and PDL-1 Inhibitors Sales Market Share by Country/Region (2024)
Figure 10. PD-1 and PDL-1 Inhibitors Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Pembrolizumab
Figure 12. Product Picture of Nivolumab
Figure 13. Product Picture of Atezolizumab
Figure 14. Product Picture of Durvalumab
Figure 15. Product Picture of Avelumab
Figure 16. Global PD-1 and PDL-1 Inhibitors Sales Market Share byType in 2025
Figure 17. Global PD-1 and PDL-1 Inhibitors Revenue Market Share byType (2020-2025)
Figure 18. PD-1 and PDL-1 Inhibitors Consumed in Stomach Cancer
Figure 19. Global PD-1 and PDL-1 Inhibitors Market: Stomach Cancer (2020-2025) & (K Units)
Figure 20. PD-1 and PDL-1 Inhibitors Consumed in Liver Cancer
Figure 21. Global PD-1 and PDL-1 Inhibitors Market: Liver Cancer (2020-2025) & (K Units)
Figure 22. PD-1 and PDL-1 Inhibitors Consumed in Kidney Ccancer
Figure 23. Global PD-1 and PDL-1 Inhibitors Market: Kidney Ccancer (2020-2025) & (K Units)
Figure 24. PD-1 and PDL-1 Inhibitors Consumed in Bladder Cancer
Figure 25. Global PD-1 and PDL-1 Inhibitors Market: Bladder Cancer (2020-2025) & (K Units)
Figure 26. PD-1 and PDL-1 Inhibitors Consumed in Cervical Cancer
Figure 27. Global PD-1 and PDL-1 Inhibitors Market: Cervical Cancer (2020-2025) & (K Units)
Figure 28. PD-1 and PDL-1 Inhibitors Consumed in Other
Figure 29. Global PD-1 and PDL-1 Inhibitors Market: Other (2020-2025) & (K Units)
Figure 30. Global PD-1 and PDL-1 Inhibitors Sale Market Share by Application (2024)
Figure 31. Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Application in 2025
Figure 32. PD-1 and PDL-1 Inhibitors Sales by Company in 2025 (K Units)
Figure 33. Global PD-1 and PDL-1 Inhibitors Sales Market Share by Company in 2025
Figure 34. PD-1 and PDL-1 Inhibitors Revenue by Company in 2025 ($ millions)
Figure 35. Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Company in 2025
Figure 36. Global PD-1 and PDL-1 Inhibitors Sales Market Share by Geographic Region (2020-2025)
Figure 37. Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Geographic Region in 2025
Figure 38. Americas PD-1 and PDL-1 Inhibitors Sales 2020-2025 (K Units)
Figure 39. Americas PD-1 and PDL-1 Inhibitors Revenue 2020-2025 ($ millions)
Figure 40. APAC PD-1 and PDL-1 Inhibitors Sales 2020-2025 (K Units)
Figure 41. APAC PD-1 and PDL-1 Inhibitors Revenue 2020-2025 ($ millions)
Figure 42. Europe PD-1 and PDL-1 Inhibitors Sales 2020-2025 (K Units)
Figure 43. Europe PD-1 and PDL-1 Inhibitors Revenue 2020-2025 ($ millions)
Figure 44. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales 2020-2025 (K Units)
Figure 45. Middle East & Africa PD-1 and PDL-1 Inhibitors Revenue 2020-2025 ($ millions)
Figure 46. Americas PD-1 and PDL-1 Inhibitors Sales Market Share by Country in 2025
Figure 47. Americas PD-1 and PDL-1 Inhibitors Revenue Market Share by Country (2020-2025)
Figure 48. Americas PD-1 and PDL-1 Inhibitors Sales Market Share byType (2020-2025)
Figure 49. Americas PD-1 and PDL-1 Inhibitors Sales Market Share by Application (2020-2025)
Figure 50. United States PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 51. Canada PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 52. Mexico PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 53. Brazil PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 54. APAC PD-1 and PDL-1 Inhibitors Sales Market Share by Region in 2025
Figure 55. APAC PD-1 and PDL-1 Inhibitors Revenue Market Share by Region (2020-2025)
Figure 56. APAC PD-1 and PDL-1 Inhibitors Sales Market Share byType (2020-2025)
Figure 57. APAC PD-1 and PDL-1 Inhibitors Sales Market Share by Application (2020-2025)
Figure 58. China PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 59. Japan PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 60. South Korea PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 61. Southeast Asia PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 62. India PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 63. Australia PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 64. ChinaTaiwan PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 65. Europe PD-1 and PDL-1 Inhibitors Sales Market Share by Country in 2025
Figure 66. Europe PD-1 and PDL-1 Inhibitors Revenue Market Share by Country (2020-2025)
Figure 67. Europe PD-1 and PDL-1 Inhibitors Sales Market Share byType (2020-2025)
Figure 68. Europe PD-1 and PDL-1 Inhibitors Sales Market Share by Application (2020-2025)
Figure 69. Germany PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 70.France PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 71. UK PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 72. Italy PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 73. Russia PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 74. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Market Share by Country (2020-2025)
Figure 75. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Market Share byType (2020-2025)
Figure 76. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Market Share by Application (2020-2025)
Figure 77. Egypt PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 78. South Africa PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 79. Israel PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 80.Turkey PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 81. GCC Countries PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 82. Manufacturing Cost Structure Analysis of PD-1 and PDL-1 Inhibitors in 2025
Figure 83. Manufacturing Process Analysis of PD-1 and PDL-1 Inhibitors
Figure 84. Industry Chain Structure of PD-1 and PDL-1 Inhibitors
Figure 85. Channels of Distribution
Figure 86. Global PD-1 and PDL-1 Inhibitors Sales MarketForecast by Region (2026-2031)
Figure 87. Global PD-1 and PDL-1 Inhibitors Revenue Market ShareForecast by Region (2026-2031)
Figure 88. Global PD-1 and PDL-1 Inhibitors Sales Market ShareForecast byType (2026-2031)
Figure 89. Global PD-1 and PDL-1 Inhibitors Revenue Market ShareForecast byType (2026-2031)
Figure 90. Global PD-1 and PDL-1 Inhibitors Sales Market ShareForecast by Application (2026-2031)
Figure 91. Global PD-1 and PDL-1 Inhibitors Revenue Market ShareForecast by Application (2026-2031)
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global PD-1 and PDL-1 Inhibitors Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for PD-1 and PDL-1 Inhibitors by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for PD-1 and PDL-1 Inhibitors by Country/Region, 2020, 2024 & 2031
2.2 PD-1 and PDL-1 Inhibitors Segment by Type
2.2.1 Pembrolizumab
2.2.2 Nivolumab
2.2.3 Atezolizumab
2.2.4 Durvalumab
2.2.5 Avelumab
2.3 PD-1 and PDL-1 Inhibitors Sales by Type
2.3.1 Global PD-1 and PDL-1 Inhibitors Sales Market Share by Type (2020-2025)
2.3.2 Global PD-1 and PDL-1 Inhibitors Revenue and Market Share by Type (2020-2025)
2.3.3 Global PD-1 and PDL-1 Inhibitors Sale Price by Type (2020-2025)
2.4 PD-1 and PDL-1 Inhibitors Segment by Application
2.4.1 Stomach Cancer
2.4.2 Liver Cancer
2.4.3 Kidney Ccancer
2.4.4 Bladder Cancer
2.4.5 Cervical Cancer
2.4.6 Other
2.5 PD-1 and PDL-1 Inhibitors Sales by Application
2.5.1 Global PD-1 and PDL-1 Inhibitors Sale Market Share by Application (2020-2025)
2.5.2 Global PD-1 and PDL-1 Inhibitors Revenue and Market Share by Application (2020-2025)
2.5.3 Global PD-1 and PDL-1 Inhibitors Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global PD-1 and PDL-1 Inhibitors Breakdown Data by Company
3.1.1 Global PD-1 and PDL-1 Inhibitors Annual Sales by Company (2020-2025)
3.1.2 Global PD-1 and PDL-1 Inhibitors Sales Market Share by Company (2020-2025)
3.2 Global PD-1 and PDL-1 Inhibitors Annual Revenue by Company (2020-2025)
3.2.1 Global PD-1 and PDL-1 Inhibitors Revenue by Company (2020-2025)
3.2.2 Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Company (2020-2025)
3.3 Global PD-1 and PDL-1 Inhibitors Sale Price by Company
3.4 Key Manufacturers PD-1 and PDL-1 Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers PD-1 and PDL-1 Inhibitors Product Location Distribution
3.4.2 Players PD-1 and PDL-1 Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PD-1 AND PDL-1 INHIBITORS BY GEOGRAPHIC REGION
4.1 World Historic PD-1 and PDL-1 Inhibitors Market Size by Geographic Region (2020-2025)
4.1.1 Global PD-1 and PDL-1 Inhibitors Annual Sales by Geographic Region (2020-2025)
4.1.2 Global PD-1 and PDL-1 Inhibitors Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic PD-1 and PDL-1 Inhibitors Market Size by Country/Region (2020-2025)
4.2.1 Global PD-1 and PDL-1 Inhibitors Annual Sales by Country/Region (2020-2025)
4.2.2 Global PD-1 and PDL-1 Inhibitors Annual Revenue by Country/Region (2020-2025)
4.3 Americas PD-1 and PDL-1 Inhibitors Sales Growth
4.4 APAC PD-1 and PDL-1 Inhibitors Sales Growth
4.5 Europe PD-1 and PDL-1 Inhibitors Sales Growth
4.6 Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Growth
5 AMERICAS
5.1 Americas PD-1 and PDL-1 Inhibitors Sales by Country
5.1.1 Americas PD-1 and PDL-1 Inhibitors Sales by Country (2020-2025)
5.1.2 Americas PD-1 and PDL-1 Inhibitors Revenue by Country (2020-2025)
5.2 Americas PD-1 and PDL-1 Inhibitors Sales by Type (2020-2025)
5.3 Americas PD-1 and PDL-1 Inhibitors Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PD-1 and PDL-1 Inhibitors Sales by Region
6.1.1 APAC PD-1 and PDL-1 Inhibitors Sales by Region (2020-2025)
6.1.2 APAC PD-1 and PDL-1 Inhibitors Revenue by Region (2020-2025)
6.2 APAC PD-1 and PDL-1 Inhibitors Sales by Type (2020-2025)
6.3 APAC PD-1 and PDL-1 Inhibitors Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe PD-1 and PDL-1 Inhibitors by Country
7.1.1 Europe PD-1 and PDL-1 Inhibitors Sales by Country (2020-2025)
7.1.2 Europe PD-1 and PDL-1 Inhibitors Revenue by Country (2020-2025)
7.2 Europe PD-1 and PDL-1 Inhibitors Sales by Type (2020-2025)
7.3 Europe PD-1 and PDL-1 Inhibitors Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa PD-1 and PDL-1 Inhibitors by Country
8.1.1 Middle East & Africa PD-1 and PDL-1 Inhibitors Sales by Country (2020-2025)
8.1.2 Middle East & Africa PD-1 and PDL-1 Inhibitors Revenue by Country (2020-2025)
8.2 Middle East & Africa PD-1 and PDL-1 Inhibitors Sales by Type (2020-2025)
8.3 Middle East & Africa PD-1 and PDL-1 Inhibitors Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of PD-1 and PDL-1 Inhibitors
10.3 Manufacturing Process Analysis of PD-1 and PDL-1 Inhibitors
10.4 Industry Chain Structure of PD-1 and PDL-1 Inhibitors
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 PD-1 and PDL-1 Inhibitors Distributors
11.3 PD-1 and PDL-1 Inhibitors Customer
12 WORLD FORECAST REVIEW FOR PD-1 AND PDL-1 INHIBITORS BY GEOGRAPHIC REGION
12.1 Global PD-1 and PDL-1 Inhibitors Market Size Forecast by Region
12.1.1 Global PD-1 and PDL-1 Inhibitors Forecast by Region (2026-2031)
12.1.2 Global PD-1 and PDL-1 Inhibitors Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global PD-1 and PDL-1 Inhibitors Forecast by Type (2026-2031)
12.7 Global PD-1 and PDL-1 Inhibitors Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 GlaxoSmithKline plc
13.1.1 GlaxoSmithKline plc Company Information
13.1.2 GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.1.3 GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 GlaxoSmithKline plc Main Business Overview
13.1.5 GlaxoSmithKline plc Latest Developments
13.2 Bristol-Myers Squibb Company
13.2.1 Bristol-Myers Squibb Company Company Information
13.2.2 Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.2.3 Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Bristol-Myers Squibb Company Main Business Overview
13.2.5 Bristol-Myers Squibb Company Latest Developments
13.3 Arcus Biosciences, Inc.
13.3.1 Arcus Biosciences, Inc. Company Information
13.3.2 Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.3.3 Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Arcus Biosciences, Inc. Main Business Overview
13.3.5 Arcus Biosciences, Inc. Latest Developments
13.4 Agenus Inc
13.4.1 Agenus Inc Company Information
13.4.2 Agenus Inc PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.4.3 Agenus Inc PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Agenus Inc Main Business Overview
13.4.5 Agenus Inc Latest Developments
13.5 F. Hoffmann-La Roche Ltd
13.5.1 F. Hoffmann-La Roche Ltd Company Information
13.5.2 F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.5.3 F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 F. Hoffmann-La Roche Ltd Main Business Overview
13.5.5 F. Hoffmann-La Roche Ltd Latest Developments
13.6 Astra Zeneca PLC
13.6.1 Astra Zeneca PLC Company Information
13.6.2 Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.6.3 Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Astra Zeneca PLC Main Business Overview
13.6.5 Astra Zeneca PLC Latest Developments
13.7 Beigene Ltd
13.7.1 Beigene Ltd Company Information
13.7.2 Beigene Ltd PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.7.3 Beigene Ltd PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Beigene Ltd Main Business Overview
13.7.5 Beigene Ltd Latest Developments
13.8 Incyte Corporation
13.8.1 Incyte Corporation Company Information
13.8.2 Incyte Corporation PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.8.3 Incyte Corporation PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Incyte Corporation Main Business Overview
13.8.5 Incyte Corporation Latest Developments
13.9 Biocad
13.9.1 Biocad Company Information
13.9.2 Biocad PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.9.3 Biocad PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Biocad Main Business Overview
13.9.5 Biocad Latest Developments
13.10 CStone Pharmaceuticals
13.10.1 CStone Pharmaceuticals Company Information
13.10.2 CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.10.3 CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 CStone Pharmaceuticals Main Business Overview
13.10.5 CStone Pharmaceuticals Latest Developments
13.11 Ono Pharmaceutical
13.11.1 Ono Pharmaceutical Company Information
13.11.2 Ono Pharmaceutical PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.11.3 Ono Pharmaceutical PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Ono Pharmaceutical Main Business Overview
13.11.5 Ono Pharmaceutical Latest Developments
13.12 Merck
13.12.1 Merck Company Information
13.12.2 Merck PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.12.3 Merck PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Merck Main Business Overview
13.12.5 Merck Latest Developments
13.13 Shanghai Junshi Bioscience Co. Ltd
13.13.1 Shanghai Junshi Bioscience Co. Ltd Company Information
13.13.2 Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.13.3 Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Shanghai Junshi Bioscience Co. Ltd Main Business Overview
13.13.5 Shanghai Junshi Bioscience Co. Ltd Latest Developments
13.14 Shanghai Henlius Biotech, Inc.
13.14.1 Shanghai Henlius Biotech, Inc. Company Information
13.14.2 Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.14.3 Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Shanghai Henlius Biotech, Inc. Main Business Overview
13.14.5 Shanghai Henlius Biotech, Inc. Latest Developments
13.15 Jiangsu HengRui Medicine Co., Ltd.
13.15.1 Jiangsu HengRui Medicine Co., Ltd. Company Information
13.15.2 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
13.15.3 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Jiangsu HengRui Medicine Co., Ltd. Main Business Overview
13.15.5 Jiangsu HengRui Medicine Co., Ltd. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. PD-1 and PDL-1 Inhibitors Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. PD-1 and PDL-1 Inhibitors Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Pembrolizumab
Table 4. Major Players of Nivolumab
Table 5. Major Players of Atezolizumab
Table 6. Major Players of Durvalumab
Table 7. Major Players of Avelumab
Table 8. Global PD-1 and PDL-1 Inhibitors Sales byType (2020-2025) & (K Units)
Table 9. Global PD-1 and PDL-1 Inhibitors Sales Market Share byType (2020-2025)
Table 10. Global PD-1 and PDL-1 Inhibitors Revenue byType (2020-2025) & ($ million)
Table 11. Global PD-1 and PDL-1 Inhibitors Revenue Market Share byType (2020-2025)
Table 12. Global PD-1 and PDL-1 Inhibitors Sale Price byType (2020-2025) & (US$/Unit)
Table 13. Global PD-1 and PDL-1 Inhibitors Sale by Application (2020-2025) & (K Units)
Table 14. Global PD-1 and PDL-1 Inhibitors Sale Market Share by Application (2020-2025)
Table 15. Global PD-1 and PDL-1 Inhibitors Revenue by Application (2020-2025) & ($ million)
Table 16. Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Application (2020-2025)
Table 17. Global PD-1 and PDL-1 Inhibitors Sale Price by Application (2020-2025) & (US$/Unit)
Table 18. Global PD-1 and PDL-1 Inhibitors Sales by Company (2020-2025) & (K Units)
Table 19. Global PD-1 and PDL-1 Inhibitors Sales Market Share by Company (2020-2025)
Table 20. Global PD-1 and PDL-1 Inhibitors Revenue by Company (2020-2025) & ($ millions)
Table 21. Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Company (2020-2025)
Table 22. Global PD-1 and PDL-1 Inhibitors Sale Price by Company (2020-2025) & (US$/Unit)
Table 23. Key Manufacturers PD-1 and PDL-1 Inhibitors Producing Area Distribution and Sales Area
Table 24. Players PD-1 and PDL-1 Inhibitors Products Offered
Table 25. PD-1 and PDL-1 Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global PD-1 and PDL-1 Inhibitors Sales by Geographic Region (2020-2025) & (K Units)
Table 29. Global PD-1 and PDL-1 Inhibitors Sales Market Share Geographic Region (2020-2025)
Table 30. Global PD-1 and PDL-1 Inhibitors Revenue by Geographic Region (2020-2025) & ($ millions)
Table 31. Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Geographic Region (2020-2025)
Table 32. Global PD-1 and PDL-1 Inhibitors Sales by Country/Region (2020-2025) & (K Units)
Table 33. Global PD-1 and PDL-1 Inhibitors Sales Market Share by Country/Region (2020-2025)
Table 34. Global PD-1 and PDL-1 Inhibitors Revenue by Country/Region (2020-2025) & ($ millions)
Table 35. Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Country/Region (2020-2025)
Table 36. Americas PD-1 and PDL-1 Inhibitors Sales by Country (2020-2025) & (K Units)
Table 37. Americas PD-1 and PDL-1 Inhibitors Sales Market Share by Country (2020-2025)
Table 38. Americas PD-1 and PDL-1 Inhibitors Revenue by Country (2020-2025) & ($ millions)
Table 39. Americas PD-1 and PDL-1 Inhibitors Sales byType (2020-2025) & (K Units)
Table 40. Americas PD-1 and PDL-1 Inhibitors Sales by Application (2020-2025) & (K Units)
Table 41. APAC PD-1 and PDL-1 Inhibitors Sales by Region (2020-2025) & (K Units)
Table 42. APAC PD-1 and PDL-1 Inhibitors Sales Market Share by Region (2020-2025)
Table 43. APAC PD-1 and PDL-1 Inhibitors Revenue by Region (2020-2025) & ($ millions)
Table 44. APAC PD-1 and PDL-1 Inhibitors Sales byType (2020-2025) & (K Units)
Table 45. APAC PD-1 and PDL-1 Inhibitors Sales by Application (2020-2025) & (K Units)
Table 46. Europe PD-1 and PDL-1 Inhibitors Sales by Country (2020-2025) & (K Units)
Table 47. Europe PD-1 and PDL-1 Inhibitors Revenue by Country (2020-2025) & ($ millions)
Table 48. Europe PD-1 and PDL-1 Inhibitors Sales byType (2020-2025) & (K Units)
Table 49. Europe PD-1 and PDL-1 Inhibitors Sales by Application (2020-2025) & (K Units)
Table 50. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales by Country (2020-2025) & (K Units)
Table 51. Middle East & Africa PD-1 and PDL-1 Inhibitors Revenue Market Share by Country (2020-2025)
Table 52. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales byType (2020-2025) & (K Units)
Table 53. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales by Application (2020-2025) & (K Units)
Table 54. Key Market Drivers & Growth Opportunities of PD-1 and PDL-1 Inhibitors
Table 55. Key Market Challenges & Risks of PD-1 and PDL-1 Inhibitors
Table 56. Key IndustryTrends of PD-1 and PDL-1 Inhibitors
Table 57. PD-1 and PDL-1 Inhibitors Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. PD-1 and PDL-1 Inhibitors Distributors List
Table 60. PD-1 and PDL-1 Inhibitors Customer List
Table 61. Global PD-1 and PDL-1 Inhibitors SalesForecast by Region (2026-2031) & (K Units)
Table 62. Global PD-1 and PDL-1 Inhibitors RevenueForecast by Region (2026-2031) & ($ millions)
Table 63. Americas PD-1 and PDL-1 Inhibitors SalesForecast by Country (2026-2031) & (K Units)
Table 64. Americas PD-1 and PDL-1 Inhibitors Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 65. APAC PD-1 and PDL-1 Inhibitors SalesForecast by Region (2026-2031) & (K Units)
Table 66. APAC PD-1 and PDL-1 Inhibitors Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 67. Europe PD-1 and PDL-1 Inhibitors SalesForecast by Country (2026-2031) & (K Units)
Table 68. Europe PD-1 and PDL-1 Inhibitors RevenueForecast by Country (2026-2031) & ($ millions)
Table 69. Middle East & Africa PD-1 and PDL-1 Inhibitors SalesForecast by Country (2026-2031) & (K Units)
Table 70. Middle East & Africa PD-1 and PDL-1 Inhibitors RevenueForecast by Country (2026-2031) & ($ millions)
Table 71. Global PD-1 and PDL-1 Inhibitors SalesForecast byType (2026-2031) & (K Units)
Table 72. Global PD-1 and PDL-1 Inhibitors RevenueForecast byType (2026-2031) & ($ millions)
Table 73. Global PD-1 and PDL-1 Inhibitors SalesForecast by Application (2026-2031) & (K Units)
Table 74. Global PD-1 and PDL-1 Inhibitors RevenueForecast by Application (2026-2031) & ($ millions)
Table 75. GlaxoSmithKline plc Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 76. GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 77. GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. GlaxoSmithKline plc Main Business
Table 79. GlaxoSmithKline plc Latest Developments
Table 80. Bristol-Myers Squibb Company Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 81. Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 82. Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Bristol-Myers Squibb Company Main Business
Table 84. Bristol-Myers Squibb Company Latest Developments
Table 85. Arcus Biosciences, Inc. Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 86. Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 87. Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Arcus Biosciences, Inc. Main Business
Table 89. Arcus Biosciences, Inc. Latest Developments
Table 90. Agenus Inc Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 91. Agenus Inc PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 92. Agenus Inc PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Agenus Inc Main Business
Table 94. Agenus Inc Latest Developments
Table 95.F. Hoffmann-La Roche Ltd Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 96.F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 97.F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98.F. Hoffmann-La Roche Ltd Main Business
Table 99.F. Hoffmann-La Roche Ltd Latest Developments
Table 100. Astra Zeneca PLC Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 101. Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 102. Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Astra Zeneca PLC Main Business
Table 104. Astra Zeneca PLC Latest Developments
Table 105. Beigene Ltd Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 106. Beigene Ltd PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 107. Beigene Ltd PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Beigene Ltd Main Business
Table 109. Beigene Ltd Latest Developments
Table 110. Incyte Corporation Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 111. Incyte Corporation PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 112. Incyte Corporation PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Incyte Corporation Main Business
Table 114. Incyte Corporation Latest Developments
Table 115. Biocad Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 116. Biocad PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 117. Biocad PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Biocad Main Business
Table 119. Biocad Latest Developments
Table 120. CStone Pharmaceuticals Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 121. CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 122. CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. CStone Pharmaceuticals Main Business
Table 124. CStone Pharmaceuticals Latest Developments
Table 125. Ono Pharmaceutical Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 126. Ono Pharmaceutical PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 127. Ono Pharmaceutical PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Ono Pharmaceutical Main Business
Table 129. Ono Pharmaceutical Latest Developments
Table 130. Merck Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 131. Merck PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 132. Merck PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. Merck Main Business
Table 134. Merck Latest Developments
Table 135. Shanghai Junshi Bioscience Co. Ltd Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 136. Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 137. Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 138. Shanghai Junshi Bioscience Co. Ltd Main Business
Table 139. Shanghai Junshi Bioscience Co. Ltd Latest Developments
Table 140. Shanghai Henlius Biotech, Inc. Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 141. Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 142. Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 143. Shanghai Henlius Biotech, Inc. Main Business
Table 144. Shanghai Henlius Biotech, Inc. Latest Developments
Table 145. Jiangsu HengRui Medicine Co., Ltd. Basic Information, PD-1 and PDL-1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 146. Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications
Table 147. Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 148. Jiangsu HengRui Medicine Co., Ltd. Main Business
Table 149. Jiangsu HengRui Medicine Co., Ltd. Latest Developments
LIST OFFIGURES
Figure 1. Picture of PD-1 and PDL-1 Inhibitors
Figure 2. PD-1 and PDL-1 Inhibitors Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global PD-1 and PDL-1 Inhibitors Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global PD-1 and PDL-1 Inhibitors Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. PD-1 and PDL-1 Inhibitors Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. PD-1 and PDL-1 Inhibitors Sales Market Share by Country/Region (2024)
Figure 10. PD-1 and PDL-1 Inhibitors Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Pembrolizumab
Figure 12. Product Picture of Nivolumab
Figure 13. Product Picture of Atezolizumab
Figure 14. Product Picture of Durvalumab
Figure 15. Product Picture of Avelumab
Figure 16. Global PD-1 and PDL-1 Inhibitors Sales Market Share byType in 2025
Figure 17. Global PD-1 and PDL-1 Inhibitors Revenue Market Share byType (2020-2025)
Figure 18. PD-1 and PDL-1 Inhibitors Consumed in Stomach Cancer
Figure 19. Global PD-1 and PDL-1 Inhibitors Market: Stomach Cancer (2020-2025) & (K Units)
Figure 20. PD-1 and PDL-1 Inhibitors Consumed in Liver Cancer
Figure 21. Global PD-1 and PDL-1 Inhibitors Market: Liver Cancer (2020-2025) & (K Units)
Figure 22. PD-1 and PDL-1 Inhibitors Consumed in Kidney Ccancer
Figure 23. Global PD-1 and PDL-1 Inhibitors Market: Kidney Ccancer (2020-2025) & (K Units)
Figure 24. PD-1 and PDL-1 Inhibitors Consumed in Bladder Cancer
Figure 25. Global PD-1 and PDL-1 Inhibitors Market: Bladder Cancer (2020-2025) & (K Units)
Figure 26. PD-1 and PDL-1 Inhibitors Consumed in Cervical Cancer
Figure 27. Global PD-1 and PDL-1 Inhibitors Market: Cervical Cancer (2020-2025) & (K Units)
Figure 28. PD-1 and PDL-1 Inhibitors Consumed in Other
Figure 29. Global PD-1 and PDL-1 Inhibitors Market: Other (2020-2025) & (K Units)
Figure 30. Global PD-1 and PDL-1 Inhibitors Sale Market Share by Application (2024)
Figure 31. Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Application in 2025
Figure 32. PD-1 and PDL-1 Inhibitors Sales by Company in 2025 (K Units)
Figure 33. Global PD-1 and PDL-1 Inhibitors Sales Market Share by Company in 2025
Figure 34. PD-1 and PDL-1 Inhibitors Revenue by Company in 2025 ($ millions)
Figure 35. Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Company in 2025
Figure 36. Global PD-1 and PDL-1 Inhibitors Sales Market Share by Geographic Region (2020-2025)
Figure 37. Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Geographic Region in 2025
Figure 38. Americas PD-1 and PDL-1 Inhibitors Sales 2020-2025 (K Units)
Figure 39. Americas PD-1 and PDL-1 Inhibitors Revenue 2020-2025 ($ millions)
Figure 40. APAC PD-1 and PDL-1 Inhibitors Sales 2020-2025 (K Units)
Figure 41. APAC PD-1 and PDL-1 Inhibitors Revenue 2020-2025 ($ millions)
Figure 42. Europe PD-1 and PDL-1 Inhibitors Sales 2020-2025 (K Units)
Figure 43. Europe PD-1 and PDL-1 Inhibitors Revenue 2020-2025 ($ millions)
Figure 44. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales 2020-2025 (K Units)
Figure 45. Middle East & Africa PD-1 and PDL-1 Inhibitors Revenue 2020-2025 ($ millions)
Figure 46. Americas PD-1 and PDL-1 Inhibitors Sales Market Share by Country in 2025
Figure 47. Americas PD-1 and PDL-1 Inhibitors Revenue Market Share by Country (2020-2025)
Figure 48. Americas PD-1 and PDL-1 Inhibitors Sales Market Share byType (2020-2025)
Figure 49. Americas PD-1 and PDL-1 Inhibitors Sales Market Share by Application (2020-2025)
Figure 50. United States PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 51. Canada PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 52. Mexico PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 53. Brazil PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 54. APAC PD-1 and PDL-1 Inhibitors Sales Market Share by Region in 2025
Figure 55. APAC PD-1 and PDL-1 Inhibitors Revenue Market Share by Region (2020-2025)
Figure 56. APAC PD-1 and PDL-1 Inhibitors Sales Market Share byType (2020-2025)
Figure 57. APAC PD-1 and PDL-1 Inhibitors Sales Market Share by Application (2020-2025)
Figure 58. China PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 59. Japan PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 60. South Korea PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 61. Southeast Asia PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 62. India PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 63. Australia PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 64. ChinaTaiwan PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 65. Europe PD-1 and PDL-1 Inhibitors Sales Market Share by Country in 2025
Figure 66. Europe PD-1 and PDL-1 Inhibitors Revenue Market Share by Country (2020-2025)
Figure 67. Europe PD-1 and PDL-1 Inhibitors Sales Market Share byType (2020-2025)
Figure 68. Europe PD-1 and PDL-1 Inhibitors Sales Market Share by Application (2020-2025)
Figure 69. Germany PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 70.France PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 71. UK PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 72. Italy PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 73. Russia PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 74. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Market Share by Country (2020-2025)
Figure 75. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Market Share byType (2020-2025)
Figure 76. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Market Share by Application (2020-2025)
Figure 77. Egypt PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 78. South Africa PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 79. Israel PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 80.Turkey PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 81. GCC Countries PD-1 and PDL-1 Inhibitors Revenue Growth 2020-2025 ($ millions)
Figure 82. Manufacturing Cost Structure Analysis of PD-1 and PDL-1 Inhibitors in 2025
Figure 83. Manufacturing Process Analysis of PD-1 and PDL-1 Inhibitors
Figure 84. Industry Chain Structure of PD-1 and PDL-1 Inhibitors
Figure 85. Channels of Distribution
Figure 86. Global PD-1 and PDL-1 Inhibitors Sales MarketForecast by Region (2026-2031)
Figure 87. Global PD-1 and PDL-1 Inhibitors Revenue Market ShareForecast by Region (2026-2031)
Figure 88. Global PD-1 and PDL-1 Inhibitors Sales Market ShareForecast byType (2026-2031)
Figure 89. Global PD-1 and PDL-1 Inhibitors Revenue Market ShareForecast byType (2026-2031)
Figure 90. Global PD-1 and PDL-1 Inhibitors Sales Market ShareForecast by Application (2026-2031)
Figure 91. Global PD-1 and PDL-1 Inhibitors Revenue Market ShareForecast by Application (2026-2031)
More Publications
Global Aid-device in Image Guided Surgery Market Growth 2024-2030
US$ 3,660.00
September 2024
108 pages
Global ECG Mobile Cardiac Monitoring Market Growth 2025-2031
US$ 3,660.00
June 2025
127 pages
Global Electrical Cardioverter Market Growth 2025-2031
US$ 3,660.00
April 2025
144 pages
Global Tipless Stone Extractors Market Growth 2024-2030
US$ 3,660.00
December 2024
99 pages
Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
September 2025
120 pages
